GEP - PROS: Gene Expression Profiling in Melanoma

David, a dermatologist from Las Vegas, presents the advantages of gene expression profiling (GEP) in melanoma diagnosis and treatment. He emphasizes the concerning mortality rates linked to malignant melanoma, highlighting that thousands of potentially preventable deaths occur annually. David asserts that the 31-gene expression profile (GEP) test can effectively risk-stratify patients for melanoma-specific survival, identifying high-risk individuals often missed by traditional staging methods. He discusses various bold claims backed by peer-reviewed studies, including that GEP-tested patients show improved survival rates compared to untested counterparts, and that GEP can pinpoint patients who can safely avoid unnecessary sentinel lymph node biopsies. He notes that, despite traditional protocols, a large number of thin melanoma patients might have occult metastases, leading to missed diagnoses and subsequent deaths. David underscores the cost-effectiveness of the 31-GEP test in reducing unnecessary procedures while maintaining diagnostic efficacy. Furthermore, he introduces the utility of a 40-gene expression profile test for identifying high-risk cutaneous squamous cell carcinoma patients who may benefit from adjuvant radiation therapy. Overall, he advocates for the integration of gene expression profiling into clinical practice to improve patient outcomes in melanoma and related skin cancers.